Document Detail


Hematological malignancies are associated with a lower interferon-a blocking activity than solid tumors.
MedLine Citation:
PMID:  18426079     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Interferon (IFN) and especially IFN-alpha exhibit clinical anti-tumor activity against various types of malignant diseases. Natural inhibitors to various cytokines and IFNs have been documented in vitro as well as in vivo. IFN inhibitors have been implicated for the ineffectiveness of IFN treatment in malignant neoplasias. The aim of this study was to investigate the incidence of the IFN inhibiting activity in serum from patients with haematological malignancies versus patients with solid tumours, as an effort to explain, just in part, the different response of these patients to IFN treatment. PATIENTS AND METHODS: Ninety patients with a clinically evident solid tumour and forty-six patients with haematological malignancies were included in the study. Serum samples from all patients were collected before any treatment and stored at -70 degrees until use. Controls sera were selected from 50 apparently healthy blood donors. Interferon-inhibiting activity as well as endogenous IFN-like activity were determined in all serum samples in a cell line highly sensitive to IFN. RESULTS: There was no endogenous IFN-like activity in any of the patients' group or controls' group. Sera from patients with haematological malignancies exhibited IFN-blocking activity at a lower percentage (21.7%) in comparison to sera from patients with solid tumours (56.6%, P<0.001), but at a significantly higher percentage in comparison to sera from controls (P<0.01). CONCLUSIONS: The fact that IFN inhibitors were detected at a significantly lower percentage in sera from patients with haematological malignancies versus patients with solid tumours, could explain in part the better response of the haematological malignancies to IFN treatment.
Authors:
K Karmaniolas; M Dalamaga; S Liatis; A Kaskara; A Rigopoulos; I N Migdalis
Related Documents :
9444429 - A multicenter study on insulin-like growth factor-i serum levels in children with chron...
12423329 - Association between increased levels of il-2 and il-15 and outcome in patients with ear...
7775959 - Follow-up of antibody responses to human papillomavirus type 16 e7 in patients treated ...
2127999 - Alpha-1-antitrypsin and chronic bronchitis in adult nigerians.
8174119 - Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small ...
9101499 - Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor ne...
7604419 - Incidence and frequency of cerebral embolic signals in patients with a similar bileafle...
12190759 - Efficacy of the proseal laryngeal mask airway during manual in-line stabilisation of th...
1449879 - High resolution ct in children with cystic fibrosis.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Research communications in molecular pathology and pharmacology     Volume:  117-118     ISSN:  1078-0297     ISO Abbreviation:  Res. Commun. Mol. Pathol. Pharmacol.     Publication Date:  2005  
Date Detail:
Created Date:  2008-04-22     Completed Date:  2008-05-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9437512     Medline TA:  Res Commun Mol Pathol Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  65-75     Citation Subset:  IM    
Affiliation:
1st Department of Internal Medicine, NIMTS Hospital, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Antineoplastic Agents / antagonists & inhibitors*,  blood*
Cell Line, Tumor
Cytopathogenic Effect, Viral / drug effects
Female
Hematologic Neoplasms / blood*
Humans
Interferon Type I, Recombinant / antagonists & inhibitors*,  blood*
Interferon-alpha / antagonists & inhibitors,  blood
Male
Middle Aged
Neoplasms / blood*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Interferon Type I, Recombinant; 0/Interferon-alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of topical application of pirfenidone ointment on thermoplasty-induced acute lameness in a d...
Next Document:  The association of MMP-1, -3 and -9 genotypes with the prognosis of HCV-related hepatocellular carci...